Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care
ISRCTN ISRCTN38988331
ClinicalTrials.gov identifier
Public title A double-blind randomised placebo-controlled trial of topical nasal steroids in 4-11 year old children with persistent bilateral Otitis Media with Effusion (OME) in primary care
Scientific title
Acronym GNOME
Serial number at source HTA 01/72/02
Study hypothesis Otitis Media with Effusion affects about 85% of children by the age of 10 and can lead to hearing loss and other problems such as speech delay, educational and behavioural impairments. Referral for surgery may rise in the UK when the MRC TARGET findings are published. Presently there are no effective temporizing medical managements for the majority of children with this condition, and there is a need to find alternatives to antibiotics.
The majority of effusions are associated with virus infections, and do not need treatment, so the children identified in practices will enter a 3 month period of watchful waiting before randomization. Children will be identified through case finding and targeted by audit on the basis of risk factors, before being invited for tympanometry, by validated and fully trained research nurses.

Only persistent cases on both sides (3 months) will be included. The intervention is of a topical intranasal steroid or placebo once a day for 3 months. We will gather baseline and outcome data on the major effect modifiers and perform Pure Tone Audiometry and microtympanometry. Outcomes will be at 1, 3, and 9 months, and will include the necessary measures for a health economic evaluation of effectiveness with modeling in analysis. In addition we will include the OM7-27 questionnaire developed by the MRC as a sensitive and specific measure of change and quality of life.

Protocol can be found at http://www.hta.ac.uk/protocols/200100720002.pdf
More details can be found at http://www.hta.ac.uk/1352

Please note that, as of 15 January 2008, the anticipated start and end dates of this trial have been updated from 1 June 2003 and 31 August 2007 to 1 September 2003 and 29 February 2008, respectively.
Lay summary
Ethics approval Not provided at time of registration.
Study design Double blind randomized placebo controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Otitis media with effusion - "glue ear"
Participants - inclusion criteria Children aged 4-11 with bilateral otits media with effusion (B+B or B+C2 tympanograms) after 3 months of watchful waiting
Participants - exclusion criteria Not provided at time of registration.
Anticipated start date 01/09/2003
Anticipated end date 29/02/2008
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration.
Interventions 1. Topical nasal steroid spray mometasone furoate + standard clinical management
2. Placebo nasal spray + standard clinical management
Primary outcome measure(s) The primary end-point will be differences in rates of clearance of bilateral effusions in children (not ears) between treated and placebo arms at 1 month. We will be using microtympanometric assessment and the modified Jerger classification of tympanograms.
Secondary outcome measure(s) Not provided at time of registration.
Sources of funding NIHR Health Technology Assessment Programme - HTA (UK)
Trial website
Publications 1. 2009 HTA monograph in http://www.ncbi.nlm.nih.gov/pubmed/19671372
2. 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/20015903
Contact name Dr  Ian  Williamson
  Address Primary Medical Care
University of Southampton
Aldermoor Health Centre
Aldermoor Close
  City/town Southampton
  Zip/Postcode SO16 5ST
  Country United Kingdom
  Tel +44 (0)23 8024 1071
  Fax +44 (0)23 8070 1125
  Email igw@soton.ac.uk
Sponsor University of Southampton (UK)
  Address Highfield
  City/town Southampton
  Zip/Postcode SO17 1BJ
  Country United Kingdom
  Tel +44 (0) 23 8059 5000
  Fax +44 (0)23 8059 3939
  Email rgoinfo@soton.ac.uk
  Sponsor website: http://www.soton.ac.uk/
Date applied 08/10/2003
Last edited 05/01/2010
Date ISRCTN assigned 09/10/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central